JP2008063322A5 - - Google Patents

Download PDF

Info

Publication number
JP2008063322A5
JP2008063322A5 JP2007194146A JP2007194146A JP2008063322A5 JP 2008063322 A5 JP2008063322 A5 JP 2008063322A5 JP 2007194146 A JP2007194146 A JP 2007194146A JP 2007194146 A JP2007194146 A JP 2007194146A JP 2008063322 A5 JP2008063322 A5 JP 2008063322A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease caused
hyperuricemia
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007194146A
Other languages
Japanese (ja)
Other versions
JP5226980B2 (en
JP2008063322A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2007194146A priority Critical patent/JP5226980B2/en
Priority claimed from JP2007194146A external-priority patent/JP5226980B2/en
Publication of JP2008063322A publication Critical patent/JP2008063322A/en
Publication of JP2008063322A5 publication Critical patent/JP2008063322A5/ja
Application granted granted Critical
Publication of JP5226980B2 publication Critical patent/JP5226980B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びユビデカレノンを含有する医薬組成物。 A pharmaceutical composition comprising an HMG-CoA reductase inhibitor, tocopherols and ubidecarenone. ＨＭＧ−ＣｏＡリダクターゼ阻害剤が、プラバスタチン、ロバスタチン、シンバスタチン、フルバスタチン、アトルバスタチン、ピタバスタチン及びロスバスタチン、並びにそれらの薬理上許容される塩からなる群より選ばれる１種又は２種以上である、請求項１に記載の医薬組成物。 The HMG-CoA reductase inhibitor is one or more selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin, and pharmacologically acceptable salts thereof. A pharmaceutical composition according to 1. ＨＭＧ−ＣｏＡリダクターゼ阻害剤が、プラバスタチンナトリウムである、請求項１に記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the HMG-CoA reductase inhibitor is pravastatin sodium. トコフェロール類が、ｄｌ−α−トコフェロール、コハク酸ｄｌ−α−トコフェロールカルシウム、酢酸ｄｌ−α−トコフェロール、ｄ−α−トコフェロール及びコハク酸ｄ−α−トコフェロールからなる群より選ばれる１種又は２種以上である、請求項１乃至請求項３から選択されるいずれか１項に記載の医薬組成物。 One or two tocopherols selected from the group consisting of dl-α-tocopherol, dl-α-tocopherol calcium succinate, dl-α-tocopherol acetate, d-α-tocopherol and d-α-tocopherol succinate The pharmaceutical composition according to any one of claims 1 to 3, which is as described above. 高尿酸血症又は高尿酸血症に起因する疾患を予防又は治療するための請求項１乃至請求項４から選択されるいずれか１項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 4, for preventing or treating hyperuricemia or a disease caused by hyperuricemia. 高尿酸血症に起因する疾患が痛風、腎障害、尿路結石及びメタボリックシンドロームからなる群より選択される少なくとも１つである請求項５に記載の医薬組成物。 6. The pharmaceutical composition according to claim 5, wherein the disease caused by hyperuricemia is at least one selected from the group consisting of gout, nephropathy, urinary calculus, and metabolic syndrome. （１）高尿酸血症又は高尿酸血症に起因する疾患、（２）血管内皮機能障害及び／又は血管内皮細胞由来血中一酸化窒素濃低下に起因する疾患、並びに（３）高脂血症又は高脂血症に起因する疾患を同時に予防又は治療するための請求項１乃至請求項４から選択されるいずれか１項に記載の医薬組成物。 (1) hyperuricemia or disease caused by hyperuricemia, (2) vascular endothelial dysfunction and / or disease caused by vascular endothelial cell-derived blood nitric oxide concentration decrease, and (3) hyperlipidemia The pharmaceutical composition according to any one of claims 1 to 4, for simultaneously preventing or treating a disease caused by symptom or hyperlipidemia. （１）高尿酸血症又は高尿酸血症に起因する疾患、（２）血管内皮機能障害及び／又は血管内皮細胞由来血中一酸化窒素濃低下に起因する疾患、並びに（３）高脂血症又は高脂血症に起因する疾患が、心血管障害症、動脈硬化症、インスリン抵抗性症状及びメタボリックシンドロームからなる群より選択される少なくとも１つである請求項７に記載の医薬組成物。 (1) hyperuricemia or disease caused by hyperuricemia, (2) vascular endothelial dysfunction and / or disease caused by vascular endothelial cell-derived blood nitric oxide concentration decrease, and (3) hyperlipidemia The pharmaceutical composition according to claim 7, wherein the disease caused by symptom or hyperlipidemia is at least one selected from the group consisting of cardiovascular disorder, arteriosclerosis, insulin resistance symptom, and metabolic syndrome. 肩こり、首すじのこり、手足のしびれ及び手足の冷えからなる群より選ばれる少なくとも１つを予防又は治療するための請求項１乃至請求項４から選択されるいずれか１項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 4, which is used for preventing or treating at least one selected from the group consisting of stiff shoulders, neck streaks, numbness of limbs and coldness of limbs.
JP2007194146A 2006-08-10 2007-07-26 Pharmaceutical composition containing an HMG-CoA reductase inhibitor, tocopherols and CoQ10 Expired - Fee Related JP5226980B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007194146A JP5226980B2 (en) 2006-08-10 2007-07-26 Pharmaceutical composition containing an HMG-CoA reductase inhibitor, tocopherols and CoQ10

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006217657 2006-08-10
JP2006217657 2006-08-10
JP2007194146A JP5226980B2 (en) 2006-08-10 2007-07-26 Pharmaceutical composition containing an HMG-CoA reductase inhibitor, tocopherols and CoQ10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012252097A Division JP2013032400A (en) 2006-08-10 2012-11-16 PHARMACEUTICAL COMPOSITION COMPRISING HMG-CoA REDUCTASE INHIBITOR, TOCOPHEROL AND CoQ10

Publications (3)

Publication Number Publication Date
JP2008063322A JP2008063322A (en) 2008-03-21
JP2008063322A5 true JP2008063322A5 (en) 2010-07-29
JP5226980B2 JP5226980B2 (en) 2013-07-03

Family

ID=39286323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007194146A Expired - Fee Related JP5226980B2 (en) 2006-08-10 2007-07-26 Pharmaceutical composition containing an HMG-CoA reductase inhibitor, tocopherols and CoQ10

Country Status (1)

Country Link
JP (1) JP5226980B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012096998A (en) * 2009-02-27 2012-05-24 Kowa Co Stable capsule preparation and method for producing the same
TWI636783B (en) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 Stable formulations of pitavastatin
WO2022129004A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Coated statin tablet comprising vitamin e acetate powder
WO2022129003A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Multiparticulate solid oral dosage form comprising statin and vitamin e

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1285650T3 (en) * 2000-05-09 2016-09-19 Kaneka Corp METHOD AND COMPOSITION FOR INHIBITION OF atherosclerosis
JP2002363073A (en) * 2001-05-09 2002-12-18 Crescendo Corporation Sport performance
JP2005187454A (en) * 2003-12-05 2005-07-14 Sankyo Co Ltd Vitamin e-containing, ldl-reducing agent and/or arteriosclelosis inhibitor composition
JP2005225870A (en) * 2004-01-16 2005-08-25 Sankyo Co Ltd Agent for promoting synthesis of blood vessel endothelial oxide and/or agent for maintaining/improving endothelial nitrogen oxide concentration

Similar Documents

Publication Publication Date Title
JP2010047616A5 (en)
RU2022100434A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING EPA AND CARDIOVASCULAR DRUG AND METHODS OF THEIR APPLICATION
JP2007523049A5 (en)
RS50419B (en) Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
JP2010528011A5 (en)
JP2015503588A5 (en)
CL2011002787A1 (en) Substituted 1-cyanoethylheterocyclylcarboxamide derivative compounds, dipeptidylpeptidase i (dppi) or cathepsin c inhibitors; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of asthma, chronic obstructive disease or allergic rhinitis.
CL2007002686A1 (en) COMPOUNDS DERIVED FROM 2H-ISOQUINOLIN-1-ONA AND 3H-QUINAZOLIN-4-ONA, RHO KINASE INHIBITORS; AND PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE OR AFFECTION.
CL2007003495A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED CONDENSED HETEROCICLES, INHIBITORS OF THE ACTIVITY OF THE AKT; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF CANCER.
RU2007126483A (en) Heterocyclic Aspartyl Protease Inhibitors
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
JP2007277267A5 (en)
WO2008058897A3 (en) Diphyllin and other lignans as a medicament for v-atpase mediated disease
JP2004537553A5 (en)
JP2008063322A5 (en)
JP2016521279A5 (en)
WO2007128086A3 (en) Novel viral replication inhibitor
EA201401042A1 (en) PHARMACEUTICAL COMPOSITION AND COMBINED DRUG, CONTAINING HMG-CoA REDUCTASE AND PHOSPHODESTERASE 4 INHIBITORS, AND THEIR APPLICATION FOR THE TREATMENT OF LUMINIUM Fungal Diseases
JP2009537554A5 (en)
JP2005200419A5 (en)
AR081032A1 (en) PHARMACEUTICAL FORMULATION IN THE FORM OF TWO-COATED TABLETS THAT INCLUDE INHIBITOR OF HMG-COA REDUCTASA AND IRBESARTAN
EP2137175A4 (en) Novel phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
JP2007534699A5 (en)
EP2392335A3 (en) Use of 24-norUDCA
WO2008020314A3 (en) Statin stabilizing dosage formulations